Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legend Biotech Corp.

http://www.legendbiotech.com

Latest From Legend Biotech Corp.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

Companies ImmunoOncology

As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma

CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.

Clinical Trials Regenerative Medicine

Stringent Regulations Hinder International Trials In China: Trade Groups

Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.

China Clinical Trials

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Strategy Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register